Omeros (NASDAQ:OMER) Stock Crosses Above 200 Day Moving Average of $3.63

Omeros Co. (NASDAQ:OMER) passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $3.63 and traded as high as $3.95. Omeros shares last traded at $3.95, with a volume of 125,211 shares changing hands.

Analyst Ratings Changes

A number of equities analysts recently commented on OMER shares. Needham & Company LLC reiterated a “hold” rating on shares of Omeros in a report on Tuesday, June 4th. StockNews.com cut Omeros from a “hold” rating to a “sell” rating in a report on Friday, May 17th.

Omeros Trading Up 2.8 %

The business has a fifty day moving average of $3.64 and a 200 day moving average of $3.64.

Omeros (NASDAQ:OMER) last issued its quarterly earnings data on Wednesday, May 15th. The biopharmaceutical company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.61) by ($0.13). On average, analysts forecast that Omeros Co. will post -1.81 EPS for the current fiscal year.

Institutional Investors Weigh In On Omeros

Hedge funds have recently bought and sold shares of the stock. Tower Research Capital LLC TRC lifted its position in Omeros by 199.9% during the fourth quarter. Tower Research Capital LLC TRC now owns 8,069 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 5,378 shares during the last quarter. Cerity Partners LLC acquired a new stake in shares of Omeros in the fourth quarter valued at approximately $71,000. Oppenheimer & Co. Inc. acquired a new stake in shares of Omeros in the first quarter valued at approximately $85,000. Coldstream Capital Management Inc. raised its position in shares of Omeros by 42.1% in the fourth quarter. Coldstream Capital Management Inc. now owns 28,130 shares of the biopharmaceutical company’s stock valued at $92,000 after buying an additional 8,335 shares in the last quarter. Finally, Empirical Financial Services LLC d.b.a. Empirical Wealth Management raised its position in shares of Omeros by 200.0% in the fourth quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 30,000 shares of the biopharmaceutical company’s stock valued at $98,000 after buying an additional 20,000 shares in the last quarter. 48.79% of the stock is currently owned by institutional investors and hedge funds.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.